Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Lise Tarnow
- Target Recruit Count
- 40
- Registration Number
- NCT00607737
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 477
- Registration Number
- NCT00604396
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Umeå, Sweden
Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT00604344
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 362
- Registration Number
- NCT00604253
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 719
- Registration Number
- NCT00605020
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Safety of Insulin Detemir in Children With Type 1 Diabetes
- Conditions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 83
- Registration Number
- NCT00605137
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Efficacy and Safety of Insulin Detemir in Type 1 Diabetes
- Conditions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 114
- Registration Number
- NCT00595374
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Zwolle, Netherlands
Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 132
- Registration Number
- NCT00592527
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Nagpur, India
Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.
- Conditions
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 176
- Registration Number
- NCT00591227
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Basal Insulins - Pharmacodynamics
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2007-12-03
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 10
- Registration Number
- NCT00566124
- Locations
- 🇩🇰
Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus, DK, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.